BioInvent International AB will be listed on June 12 - The Offering was subscribed to 2.5 times

BioInvent International AB will be listed on June 12 The Offering was subscribed to 2.5 times Lund, Sweden: On June 12, 2001 the biotechnology company BioInvent International AB will be listed on the O-list of the Stockholm Exchange. The Offering was subscribed to 2.5 times and the issue price has been set at SEK 62 per share. Great interest has been shown in the transaction among both Swedish and foreign institutional investors. At the time of the listing, BioInvent will have about 1,400 shareholders, of which 40 will be institutional investors within and outside Sweden. The transaction involves 6,000,000 shares and consists of the issue of 4,500,000 new shares and the sale of 1,500,000 shares belonging to a number of the Company's owners. The funds raised through the new share issue, amounting to SEK 279 million before issue costs are deducted, will primarily be used to pursue product development in the area of protein arrays and for the development of proprietary therapeutic antibodies as well as for current operations. In addition to the shares in the Offering, certain shareholders have issued an over-allotment option which entitles D. Carnegie AB to acquire a maximum of 750,000 shares at the issue price to cover over-allotment in connection with the Offering. BioInvent will be listed on the Stockholm Exchange's O-list with the abbreviation BINV. The first listing day is June 12, 2001. D. Carnegie AB is acting as Sole Lead Manager and Bookrunner in conjunction with the new share issue and the listing. For further information, please contact: BioInvent International AB Svein Mathisen President and Chief Executive Officer Telephone: +46 (0)46 286 85 67 Mobile: +46 (0)708 97 82 13 E-mail: Buchanan Communications Nicola How / Edward Cowdery Telephone: +44 (0)20 7466 5000 BioInvent International AB is a privately held biotechnology company devoted to providing state-of-the-art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeRTM . This is a collection of more than ten billion functional antibody genes which are ready to be screened against desired antigens. n-CoDeRTM has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeRTM through collaborative research and development programs. BioInvent's capabilities in large scale contract manufacturing of protein based drugs through a state-of-the-art cGMP - certified facility further underpins its competitiveness on the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified production facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total 100 people. Visit our website ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download:

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at